[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100652580":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":14,"responsibleParty":32,"collaborators":7,"id":36,"slug":37,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":41,"acronym":42,"eligibilityCriteria":43,"healthyVolunteers":38,"sex":44,"minAge":45,"maxAge":7,"enrollmentInfo":46,"targetDuration":49,"studyType":50,"phases":7,"briefSummary":51,"conditions":52,"keywords":54,"overallStatus":17,"whyStopped":7,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":66},{"fullName":5,"class":6},"Università degli Studi 'G. d'Annunzio' Chieti e Pescara","OTHER",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Carmine Liberatore, MD","CONTACT","+390854252853","carmine.liberatore@unich.it",[15],{"facility":16,"status":17,"city":18,"state":19,"zip":20,"country":21,"countryCode":22,"cosmosGeoPoint":23,"geoPoint":28,"contacts":29},"Dipartimento di Medicina e Scienze dell'Invecchiamento, Università degli Studi \"G. d'Annunzio\" di Chieti - Pescara","RECRUITING","Chieti","CH","66100","Italy","IT",{"type":24,"coordinates":25},"Point",[26,27],14.16494,42.34827,{"lat":27,"lon":26},[30],{"name":10,"role":11,"phone":31,"phoneExt":7,"email":13},"+390854251",{"type":33,"investigatorFullName":34,"investigatorTitle":35,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Carmine Liberatore","Principal Investigator","100652580","real-life-study-on-the-use-of-allogeneic-hematopoietic-stem-cell-transplantation-in-patients-with-relapsedrefractory-multiple-myeloma-100652580",false,"NCT07777406","Real-life Study on the Use of Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Relapsed\u002FRefractory Multiple Myeloma","Studio Real-life Sull'Utilizzo Del Trapianto Allogenico di Cellule Staminali Ematopoietiche in Pazienti Affetti da Mieloma Multiplo Recidivato Refrattario","MAIELLA","Inclusion Criteria:\n\n* patients diagnosed with relapsed\u002Frefractory multiple myeloma according to IMWG criteria who have undergone allogeneic hematopoietic stem cell transplantation;\n* Age ≥ 18 years;\n* Signature of the informed consent form (where possible).\n\nExclusion Criteria:\n\n* Patients diagnosed with primary AL amyloidosis, monoclonal gammopathy of undetermined significance (MGUS), indolent multiple myeloma, or primary plasma cell leukemia;\n* Patients who have not undergone allogeneic hematopoietic stem cell transplantation;\n* Age \\\u003C 18 years.","ALL","18 Years",{"count":47,"type":48},60,"ESTIMATED","24 Months","OBSERVATIONAL","A multicenter, non-interventional, observational, retrospective and prospective pharmacological study aimed at evaluating the use of allogeneic hematopoietic stem cell transplantation in patients with relapsed\u002Frefractory multiple myeloma.",[53],"Plasma Cell Neoplasms",[55,56],"multiple myeloma","allogeneic hematopoietic stem cell transplantation","2026-08-18",{"date":59,"type":60},"2026-08-20","ACTUAL",{"date":62,"type":60},"2026-03-24",{"date":64,"type":48},"2027-12-31",{"name":5,"class":6},1]